Volume matters: The influence of different botulinum toxin-A dilutions for sialorrhea in amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 47, Issue 2, 2013, Pages 276-278

  Evangelos, Anagnostou ^a   Michael, Rentzos ^a   Theodoros, Alexakis ^a   Vasiliki, Zouvelou ^a   Thomas, Zambelis ^a   Ioannis, Evdokimidis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Amyotrophic lateral sclerosis; Botulinum toxin; Drooling; Palliative; Sialorrhea

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; DILUTION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HYPERSALIVATION; MALE; PRIORITY JOURNAL; RATING SCALE; SWALLOWING; VISUAL ANALOG SCALE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SIALORRHEA; TREATMENT OUTCOME;

EID: 84873019526     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23692     Document Type: Article

References (14)

1. Tscheng DZ. Sialorrhea - therapeutic drug options. Ann Pharmacother 2002; 36: 1785-1790.
2. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses 1997; 48: 337-339.
3. Molloy L. Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence. Curr Opin Neurol 2007; 20: 493-499.
4. Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, et al. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 299-303.
5. Gilio F, Iacovelli E, Frasca V, Gabriele M, Giacomelli E, Picchiori F, et al. Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotroph Lateral Scler 2010; 11: 359-363.
6. Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001; 190: 95-97.
7. Meijer JWG, van Kuijk AA, Geurts ACH, Schelhaas JH, Zwarts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil 2008; 87: 321-324.
8. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil 2004; 83: S30-S70.
9. Package insert on Botox, Irvine, California, USA, Allergan, Inc; October 2010.
10. Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 2006; 34: 235-237.
11. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121-123.
12. Scott KR, Kothari MJ, Venkatesh YS, Murphy T, Simmons Z. Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis 2005; 7: 62-65.
13. Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol 2008; 255: 545-550.
14. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al; Muscle Study Group. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39: 137-143.